scholarly journals Down-regulation of the Anti-inflammatory Protein Annexin A1 in Cystic Fibrosis Knock-out Mice and Patients

2005 ◽  
Vol 4 (10) ◽  
pp. 1591-1601 ◽  
Author(s):  
Noura Bensalem ◽  
Ana Paula Ventura ◽  
Benoît Vallée ◽  
Joanna Lipecka ◽  
Danielle Tondelier ◽  
...  
Blood ◽  
2012 ◽  
Vol 119 (10) ◽  
pp. 2422-2429 ◽  
Author(s):  
Zhuang Wu ◽  
Ming-Cheh Liu ◽  
Mei Liang ◽  
Jian Fu

Abstract Exposure to ambient particulate matter (PM) air pollution has been reported to trigger inflammation and thrombosis. However, molecular mechanisms underlying the modulation of coagulation pathways in PM-induced thrombosis remain largely unknown. We report here that Sirt1, a member of class III histone deacetylase, controls lung inflammation and coagulation after PM exposure. Sirt1 knock-out mice exhibited aggravated lung vascular leakage and inflammation after PM exposure, which was correlated with increased NF-κB acetylation and activation. Furthermore, Sirt1 knock-out mice were highly susceptible to PM-induced lung coagulation as demonstrated by increased fibrin formation. The increased fibrin formation was associated with reduced tissue factor pathway inhibitor (TFPI) expression and increased plasminogen activator inhibitor-1 (PAI-1) activity in the lungs, thus favoring elevated coagulation and disrupted fibrinolysis responses. Thrombomodulin (TM), a central player of the anticoagulant protein C system, is regulated by Kruppel-like factor 2 (KLF2) at the transcriptional level. Our data show that PM exposure led to decreased lung KLF2 and TM expression in wild-type mice, and lung KLF2 and TM protein levels were further decreased in Sirt1 knock-out mice. Importantly, Sirt1 gene delivery inhibited TM and KLF2 down-regulation and reduced lung coagulation after PM exposure. Collectively, our studies indicate that Sirt1 functions as a suppressor of coagulation after particulate matter exposure.


2011 ◽  
Vol 25 (S1) ◽  
Author(s):  
Stephan Frank Hohberger ◽  
Daniel Brand ◽  
Tanja Loof ◽  
Harm Peters ◽  
Sebastian Bachmann ◽  
...  

2020 ◽  
pp. 2000261
Author(s):  
Mathias Declercq ◽  
Pauline de Zeeuw ◽  
Nadine Vasconcelos Conchinha ◽  
Vincent Geldhof ◽  
Anabela S. Ramalho ◽  
...  

Cystic fibrosis (CF) is a life-threatening disorder characterised by decreased pulmonary mucociliary and pathogen clearance, and an exaggerated inflammatory response leading to progressive lung damage. CF is caused by bi-allelic pathogenic variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes a chloride channel. CFTR is expressed in endothelial cells (ECs) and EC dysfunction has been reported in CF patients, but a role for this ion channel in CF disease progression is poorly described.We used an unbiased RNA sequencing approach in complementary models of CFTR silencing and blockade (by the CFTR inhibitor CFTRinh-(172)) in human ECs to characterise the changes upon CFTR impairment. Key findings were further validated in vitro, in vivo in CFTR knock-out mice and ex vivo in CF patient-derived ECs.Both models of CFTR impairment revealed that EC proliferation, migration and autophagy were downregulated. Remarkably though, defective CFTR function led to EC activation and a persisting pro-inflammatory state of the endothelium with increased leukocyte adhesion. Further validation in CFTR knock-out mice revealed enhanced leukocyte extravasation in lung and liver parenchyma associated with increased levels of EC activation markers. In addition, CF patient-derived ECs displayed increased EC activation markers and leukocyte adhesion, which was partially rescued by using CFTR modulators VX770-VX809.Our integrated analysis thus suggests that ECs are no innocent bystanders in CF pathology, but rather may contribute to the exaggerated inflammatory phenotype, raising the question whether normalisation of vascular inflammation might be a novel therapeutic strategy to ameliorate the disease severity of CF.


2005 ◽  
Vol 4 (11) ◽  
pp. 1762-1775 ◽  
Author(s):  
Franck Brouillard ◽  
Noura Bensalem ◽  
Alexandre Hinzpeter ◽  
Danielle Tondelier ◽  
Stéphanie Trudel ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3524
Author(s):  
Ajantha Sinniah ◽  
Samia Yazid ◽  
Rod J. Flower

Our interest in inflammation and its treatment stems from ancient times. Hippocrates used willow bark to treat inflammation, and many centuries later, salicylic acid and its derivative aspirin’s ability to inhibit cyclooxygenase enzymes was discovered. Glucocorticoids (GC) ushered in a new era of treatment for both chronic and acute inflammatory disease, but their potentially dangerous side effects led the pharmaceutical industry to seek other, safer, synthetic GC drugs. The discovery of the GC-inducible endogenous anti-inflammatory protein annexin A1 (AnxA1) and other endogenous proresolving mediators has opened a new era of anti-inflammatory therapy. This review aims to recapitulate the last four decades of research on NSAIDs, GCs, and AnxA1 and their anti-inflammatory effects.


Sign in / Sign up

Export Citation Format

Share Document